BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38403964)

  • 1. Polymer-Drug Conjugates Codeliver a Temozolomide Intermediate and Nitric Oxide for Enhanced Chemotherapy against Glioblastoma Multiforme.
    Du K; Li X; Feng F
    ACS Appl Bio Mater; 2024 Mar; 7(3):1810-1819. PubMed ID: 38403964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy.
    Du K; Xia Q; Sun J; Feng F
    ACS Appl Mater Interfaces; 2021 Dec; 13(47):55851-55861. PubMed ID: 34788006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme.
    Li X; Shao F; Sun J; Du K; Sun Y; Feng F
    ACS Appl Mater Interfaces; 2019 Nov; 11(45):41935-41945. PubMed ID: 31644262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomimetic Polymer-Templated Copper Nanoparticles Stabilize a Temozolomide Intermediate for Chemotherapy against Glioblastoma Multiforme.
    Wang X; Hu A; Du K; Feng F
    ACS Appl Bio Mater; 2021 Nov; 4(11):8004-8012. PubMed ID: 35006781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme.
    Jatyan R; Singh P; Sahel DK; Karthik YG; Mittal A; Chitkara D
    J Control Release; 2022 Oct; 350():494-513. PubMed ID: 35985493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SNAP reverses temozolomide resistance in human glioblastoma multiforme cells through down-regulation of MGMT.
    Tsai CK; Huang LC; Wu YP; Kan IY; Hueng DY
    FASEB J; 2019 Dec; 33(12):14171-14184. PubMed ID: 31725331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
    Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A
    J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
    Lan F; Pan Q; Yu H; Yue X
    J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
    Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
    Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific transport of temozolomide does not override DNA repair-mediated chemoresistance.
    Bahrami K; Kärkkäinen J; Bibi S; Huttunen J; Tampio J; Montaser AB; Moody CL; Lehtonen M; Rautio J; Wheelhouse RT; Huttunen KM
    Eur J Pharm Sci; 2024 Apr; 195():106661. PubMed ID: 38052257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.
    Petrenko D; Chubarev V; Syzrantsev N; Ismail N; Merkulov V; Sologova S; Grigorevskikh E; Smolyarchuk E; Alyautdin R
    Molecules; 2022 May; 27(11):. PubMed ID: 35684445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of Temozolomide and N3-Propargyl Analog to Brain Tumors Using an Apoferritin Nanocage.
    Bouzinab K; Summers HS; Stevens MFG; Moody CJ; Thomas NR; Gershkovich P; Weston N; Ashford MB; Bradshaw TD; Turyanska L
    ACS Appl Mater Interfaces; 2020 Mar; 12(11):12609-12617. PubMed ID: 32073826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric Oxide Prevents Glioblastoma Stem Cells' Expansion and Induces Temozolomide Sensitization.
    Salvatori L; Malatesta S; Illi B; Somma MP; Fionda C; Stabile H; Fontanella RA; Gaetano C
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy.
    Ramalho MJ; Andrade S; Coelho MÁN; Loureiro JA; Pereira MC
    Eur J Pharm Biopharm; 2019 Mar; 136():156-163. PubMed ID: 30682492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide-fatty acid conjugates for glioblastoma multiforme: In vitro and in vivo evaluation.
    Jatyan R; Sahel DK; Singh P; Sakhuja R; Mittal A; Chitkara D
    J Control Release; 2023 Jul; 359():161-174. PubMed ID: 37182806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
    Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
    BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
    Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
    Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
    Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
    Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.